If you walked into most pharma bid management teams in India and asked them whether they are working hard, the answer would be an unambiguous yes. These are not teams with a motivation problem or an effort problem. They are working long hours, managing multiple simultaneous deadlines, chasing documents across departments, and trying to keep pace with a procurement landscape that spans dozens of portals and hundreds of potential opportunities at any given time.

And yet win rates stay stubbornly low. Participation remains a fraction of what it could be. The same disqualification reasons recur quarter after quarter. Pricing decisions feel like guesswork dressed up as analysis. And at the end of every tender cycle, the team is exhausted but the revenue number from institutional procurement has barely moved.

This is not a hard work problem. It is a work composition problem. The bid team is busy, but most of what they are busy with is not the work that actually determines whether a tender is won or lost. The hours that should be going into strategic bid positioning, competitive pricing analysis, and quality response crafting are instead going into portal monitoring, document hunting, format conversion, and deadline tracking. These are necessary tasks but they are not skilled tasks, and the fact that skilled people are doing them is where the productivity breakdown actually lives.

What a Bid Manager's Day Actually Looks Like

It is worth being specific about this because the problem is easier to dismiss in the abstract than when you look at the actual time allocation of a working bid management team.

A bid manager's morning typically starts with checking portals. GEM, CPPP, state procurement portals, hospital procurement pages, any other sources that are relevant for the company's product portfolio. This is not a quick scan. Each portal has its own interface, its own notification system, and its own degree of reliability. Some portals are well-maintained and surface new tenders clearly. Others require navigating multiple layers to find what has been posted recently. A thorough morning check across eight to ten portals takes anywhere from 45 minutes to two hours, and at the end of it the bid manager may or may not have found something worth acting on.

When a relevant tender is identified, the next task is reading it. A government pharmaceutical tender document in India is not a short document. It routinely runs to 200, 300, sometimes 500 pages including all schedules, annexures, and addenda. Reading it carefully enough to understand the eligibility requirements, the technical specifications, the documentation requirements, the penalty clauses, the delivery terms, and the evaluation criteria is a full-day exercise for a single tender. Most bid managers do not have a full day to spend on a single document because there are three other tenders simultaneously at different stages of preparation.

So they skim. They rely on experience to know where the important clauses tend to live. They miss things, not because they are not careful but because the volume of material relative to the time available makes complete coverage impossible.

After the read comes the eligibility check. Do we have the right certifications for this product in this state? Is our turnover certificate from the right fiscal year? Does our GMP certification cover this facility? These questions require checking against physical or digital document stores that are often not well organized. The bid manager sends emails to the regulatory team, follows up when replies do not come, reconciles conflicting information about whether a particular certificate is still valid.

Then comes document assembly. Collecting every required document, verifying it is the current version, converting formats where necessary, organizing it according to the tender's specific requirements. This alone can take half a day for a complex submission.

Then pricing. Which requires getting cost inputs from finance, logistics costs from the supply chain team, and some kind of market intelligence about what competitive prices look like. The finance team has their own priorities. Getting a cost sheet that is accurate enough to base a bid on requires back-and-forth that consumes time on both sides.

Then drafting the response itself. Then internal review. Then submission. Then tracking the outcome and filing whatever institutional knowledge can be extracted from the experience before the next cycle begins.

Look at that workflow honestly and ask how much of it requires the judgment, experience, and strategic capability of a skilled bid professional. The portal checking does not. The document reading for standard clause extraction does not. The eligibility verification against a known checklist does not. The document collection and formatting does not. The deadline tracking does not.

What requires genuine skill and judgment is the eligibility assessment for edge cases, the pricing strategy, the response crafting where differentiation matters, the go or no-go decision on marginal opportunities, and the relationship management in private hospital procurement. These are the tasks where a good bid manager creates value that a less experienced person or an automated system cannot replicate.

In most bid teams, these high-value tasks get whatever time is left after everything else is done. Which is usually not much.

The Participation Ceiling Nobody Acknowledges

There is a consequence of this time allocation problem that does not get discussed directly enough in pharma commercial conversations, and it is probably the most expensive part of the problem.

Manual bid management has a hard ceiling on participation volume. A team of four to six people working manual processes can realistically pursue 20 to 30 tenders per quarter with any degree of quality. Beyond that, quality degrades, errors increase, and the team burns out.

The issue is that a mid-size pharma company with a reasonably broad product portfolio is technically eligible for far more than 20 to 30 tenders per quarter across the full procurement landscape. GEM alone has thousands of active pharmaceutical tenders at any given time. Add state health department tenders, ESIC, CGHS, Railways, and private hospital procurement, and the total addressable tender pipeline for a well-positioned company is an order of magnitude larger than what a manual team can address.

This means that the participation ceiling is not set by market opportunity or by the company's product capabilities. It is set by how much manual work a small team can process before they hit their limit. That is a costly constraint because the incremental cost of pursuing an additional tender, once the discovery and eligibility screening are done, is relatively low. The marginal revenue from winning it can be significant. The participation ceiling artificially suppresses both.

Most pharma companies have accepted this ceiling as a fact of life rather than a problem to solve. It is not a fact of life. It is an artifact of how bid management work is currently organized. And as we have written about separately, the losses that result from this ceiling often begin well before a bid is ever filed. The preparation gap, the documentation disorganization, the absence of pricing intelligence: these are structural problems that compound the workload problem rather than existing independently of it. If you have not read that piece, it covers the pre-bid failure modes in detail: Why Most Pharma Companies Are Losing on Government Tenders Before the Bid Is Even Filed.

The Institutional Memory Problem

There is another dimension to the busy-but-not-winning problem that compounds over time and gets less attention than the workload issue.

Every tender cycle generates information that would be valuable in future cycles. What price cleared the L1 position in a particular state for a particular molecule last quarter. Which clauses in a particular state's tender format consistently create compliance risk. Which hospital procurement teams weight technical quality heavily versus which are primarily price-driven. What the competitive landscape looked like in a specific product category across the last three tender cycles.

This information exists. It is generated naturally as a byproduct of the bid management process. But in a manual operation, it lives in bid managers' heads, in email threads, in folders on individual laptops, in notes that get lost when people change roles or leave the organization. It is not systematically captured, organized, and made available to inform the next decision.

The practical consequence is that the bid team effectively starts close to zero on institutional knowledge with each new tender cycle. They make the same pricing mistakes they made a year ago because nobody recorded what they learned. They miss the same compliance traps because the person who encountered them last time has moved on. They lose on price in markets where they could have been more aggressive because they have no reliable record of where the market cleared previously.

Experienced bid managers carry a lot of this knowledge personally, which is valuable as long as they stay. When they leave, as people do, the knowledge walks out with them. The team that replaces them rebuilds it from scratch over the next several cycles.

This is an organizational capability problem, not a people problem. The information needed to make better decisions is being generated. It is just not being preserved in a form that the organization can use.

Why the Standard Solutions Have Not Fixed This

The pharma industry has tried various approaches to the bid team productivity problem and none of them have solved it in any fundamental way.

Hiring more bid managers is the most common response. If the team cannot keep up with the workload, add headcount. This works to a point but it does not change the work composition problem. Additional bid managers do the same mix of high-value and low-value tasks. The participation ceiling rises but so does the cost base, and the institutional knowledge problem remains.

Better document management systems help with the document hunting problem but do not address the portal monitoring, the eligibility screening, the pricing analysis, or the response drafting. They solve one piece of the workflow and leave the rest unchanged.

Standardized response templates reduce the time required for response drafting but at the cost of differentiation. A template that works for 80 percent of tenders still requires significant customization for the other 20 percent, and the tenders that require the most customization are often the highest-value opportunities.

Dedicated pricing teams help with the pricing quality problem but create coordination overhead between the pricing function and the bid preparation function that can actually slow the process down on tighter deadlines.

None of these approaches address the root cause, which is that the work composition of bid management is heavily weighted toward tasks that do not require human judgment, and as long as that remains true, skilled bid managers will continue spending most of their time on work that does not leverage what makes them valuable. The broader shift happening in how AI is being applied to this problem across the industry is worth understanding in its own right. We covered the full landscape of what AI-powered tender management actually enables, and why adoption is accelerating, in this piece: How AI Is Transforming Tender and RFP Management in India and Why Your Competitors Are Already Using It.

What the Work Should Actually Look Like

The bid management function in a well-organized pharma company should look fundamentally different from what it currently looks like in most organizations.

The discovery and monitoring work should be automatic. Every relevant tender across every relevant portal should surface to the bid team without anyone spending time checking portals manually. The filtering should happen before human eyes touch the opportunity, based on product catalog match, geographic eligibility, and rough commercial fit. The bid manager's first interaction with an opportunity should be a pre-screened, pre-assessed tender with a recommendation on whether it is worth pursuing, not a raw portal notification that requires hours of work to evaluate.

The document parsing work should be automatic. A 400-page tender document should not require a bid manager to read it cover to cover to extract the requirements, deadlines, eligibility criteria, and compliance obligations. That extraction should happen in minutes and produce a structured summary that the bid manager reviews and acts on rather than builds from scratch.

The eligibility screening should be automatic against a live database of the company's certifications, their validity, and their applicable scope. The bid manager should be told whether the company is eligible, with any gaps clearly identified, rather than spending time performing that check manually.

The first draft of a bid response should be assembled automatically from the company's existing response library and product documentation, structured to the specific tender's requirements. The bid manager's job should be to review, refine, and add the strategic and differentiating elements that require genuine judgment, not to build the document from a blank page.

The pricing analysis should arrive pre-populated with cost inputs from finance systems, benchmarked against historical award data for comparable tenders, with scenario options that the bid manager and the CFO can review and decide on rather than construct from scratch.

When the work is organized this way, the bid team's capacity changes dramatically. Not because they are working harder but because the hours that were going into low-value administrative work are now available for the high-value judgment work that actually moves win rates. The same team that previously managed 25 tenders per quarter can now manage 80 or 100, with better quality on each one because the structural work is handled and their attention is concentrated where it matters. If you want to see what this looks like end to end in practice, the full workflow is detailed here: AI RFP and Pharma Tender Automation by SwishX.

The Compound Effect on Revenue

The commercial impact of fixing this problem is not incremental. It is structural.

More tenders pursued means more shots at revenue. Better quality responses mean higher win rates on the tenders pursued. Better pricing intelligence means better margins on the tenders won. Better institutional memory means the improvement compounds over time rather than resetting with each personnel change.

A bid team that is genuinely operating at its potential, focused on strategic and judgment-intensive work rather than administrative processing, is a different kind of commercial asset than one that is buried in manual tasks. The revenue gap between these two operating modes, for a mid-size pharma company with a relevant product portfolio, is not marginal. It is the difference between institutional procurement being a meaningful revenue line and it being an afterthought that consumes resources without delivering proportionate returns.

The bid team is not the problem. What they are being asked to spend their time on is.

‍